Key result
Anthracyclines remain central to non-Hodgkin's lymphoma treatment, and strategies such as liposome-encapsulated doxorubicin can reduce cardiotoxicity while maintaining antitumor efficacy.
Strategies such as liposome-encapsulated doxorubicin and dexrazoxane can mitigate the cardiotoxic effects of anthracyclines in patients with non-Hodgkin's lymphoma.
May support liposomal doxorubicin in NHL to limit cardiotoxicity; leaves open need for prospective RCTs.
Anthracyclines have a central role in the management of non-Hodgkin's lymphoma (NHL). The cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment regimen has been the standard of care for more than 20 years. Further improvements have been made to the efficacy of this chemotherapy by reducing the dosing interval and adding rituximab to the regimen. A major limitation to the use of anthracyclines is the development of cardiotoxicity as a late adverse event. Strategies to reduce cardiac events include changes to the dosing schedule for doxorubicin, use of the chelating agent dexrazoxane and the use of liposome-encapsulated doxorubicin. This latter strategy has demonstrated good efficacy and reduced cardiotoxicity in patients with NHL, including those at risk of developing cardiac effects.
No takes yet. Share an insight, caveat, or question.
Dino Amadori (2011) conducted a review in Non-Hodgkin's lymphoma. Anthracyclines and liposome-encapsulated doxorubicin was evaluated. Anthracyclines remain central to non-Hodgkin's lymphoma treatment, and strategies such as liposome-encapsulated doxorubicin can reduce cardiotoxicity while maintaining antitumor efficacy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: